menu
    • menu

    Company profile for Allogene Therapeutics

    NEW Drugs in Dev: 10
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Allogene Therapeutics is a clinical stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR TTM) therapies for cancer. Led by a world-class management team with significant experience in cell therapy, we are developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably and at greater scale to more patients.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Allogene TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    210 E. Grand Avenue South San Francisco, CA 94080
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://allogene.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/allogene-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/AllogeneTx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Allogene Therapeutics Reveals ALLO-329, Pre-Clinical Data
    Allogene Therapeutics Reveals ALLO-329, Pre-Clinical Data

    15 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7181784

    FIRSTWORD PHARMA
    15 Apr 2026
    Share Share
    Allogene CAR T Shows Promise In Clearing Residual Lymphoma
    Allogene CAR T Shows Promise In Clearing Residual Lymphoma

    13 Apr 2026

    // BIOSPACE

    https://www.biospace.com/drug-development/allogene-stock-sails-after-car-t-clears-residual-lymphoma-in-early-data-cut

    BIOSPACE
    13 Apr 2026
    Share Share
    Allogene Therapeutics Plans $175M Public Stock Offering
    Allogene Therapeutics Plans $175M Public Stock Offering

    13 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/13/3272887/0/en/Allogene-Therapeutics-Announces-Proposed-Public-Offering-of-175-Million-of-Common-Stock.html

    GLOBENEWSWIRE
    13 Apr 2026
    Share Share
    Cellectis' Cema-Cel Shows Strength In Pivotal Trial Interim Data
    Cellectis' Cema-Cel Shows Strength In Pivotal Trial Interim Data

    13 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/13/3272912/0/en/Cema-Cel-Pivotal-Trial-Interim-Data-Highlight-Strength-of-Cellectis-Allogeneic-CAR-T-Platform.html

    GLOBENEWSWIRE
    13 Apr 2026
    Share Share
    Allogene Therapeutics To Release Interim Data On Cema-Cel
    Allogene Therapeutics To Release Interim Data On Cema-Cel

    10 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/10/3272027/0/en/Allogene-Therapeutics-to-Announce-Interim-Futility-Analysis-Data-from-its-Pivotal-Phase-2-ALPHA3-Trial-with-Cemacabtagene-Ansegedleucel-Cema-Cel-in-First-Line-Consolidation-LBCL-on.html

    GLOBENEWSWIRE
    10 Apr 2026
    Share Share
    Allogene Therapeutics Reveals 2025 Financials And Business Update
    Allogene Therapeutics Reveals 2025 Financials And Business Update

    12 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/12/3255086/0/en/Allogene-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Business-Update.html

    GLOBENEWSWIRE
    12 Mar 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search